March 10 (Reuters) -
- IMMUTEP LTD - RECEIVES CONSTRUCTIVE FEEDBACK FROM US FDA ON ITS CLINICAL DEVELOPMENT PROGRAM FOR EFTI IN METASTATIC BREAST CANCER
- IMMUTEP LTD - FDA HAS SUPPORTED IMMUTEP'S VIEW TO CONTINUE EXPLORING DEVELOPMENT OF EFTI IN MBC IN A NEW REGISTRATIONAL TRIAL
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $359.6M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 24.5¢ | $71.74K | 288.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 284923 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 176127 | 13 |
View Market Depth
| Last trade - 11.25am 18/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |